10-Q: Celcuity Reports Strong Phase 3 Breast Cancer Data, Secures $286M in Financing

Celcuity Inc. announced positive Phase 3 clinical trial results for gedatolisib in HR+/HER2advanced breast cancer and significantly bolstered its liquidity with over $286 million in new financing.

Summary

• Celcuity reported a net loss of $43.8 million for the three months ended September 30, 2025, a 47% increase from $29.8 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was $126.1 million, up 68% from $75.1 million in the prior year period.
• Research and development expenses increased by 27% to $34.9 million for the three months and 52% to $107.4 million for the nine months ended September 30, 2025, driven by clinical trial activities and commercial launch preparations.
• General and administrative expenses surged by 221% to $7.9 million for the three months and 156% to $15.6 million for the nine months ended September 30, 2025, largely due to increased employee and consulting expenses, including stock-based compensation.
• The company's cash and cash equivalents, along with short-term investments, totaled approximately $455.0 million as of September 30, 2025.
• Celcuity completed a July 2025 Equity Offering, raising approximately $91.6 million in net proceeds.
• A July 2025 Convertible Notes Offering generated approximately $194.9 million in net proceeds from $201.3 million aggregate principal amount of 2.750% Senior Notes due 2031.
• The Third Amendment to the A&R Loan Agreement on September 9, 2025, resulted in the immediate disbursement of a $30.0 million Term D Loan, with net proceeds of approximately $27.8 million.
• Topline data from the PIK3CA wild-type (WT) cohort of the Phase 3 VIKTORIA-1 clinical trial showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) for gedatolisib triplet and doublet regimens.
• The gedatolisib triplet reduced the risk of disease progression or death by 76% (HR 0.24) compared to fulvestrant, with a median PFS of 9.3 months versus 2.0 months.
• The gedatolisib doublet reduced the risk of disease progression or death by 67% (HR 0.33) compared to fulvestrant, with a median PFS of 7.4 months versus 2.0 months.
• Enrollment for the PIK3CA mutant-type (MT) cohort of the VIKTORIA-1 trial is complete, with topline data expected in late Q1 2026 or Q2 2026.
• The Phase 3 VIKTORIA-2 clinical trial for first-line HR+/HER2advanced breast cancer is currently enrolling patients, with the first patient dosed in July 2025.
• Preliminary data from the CELC-G-201 Phase 1b/2 trial in metastatic castration resistant prostate cancer (mCRPC) showed a 6-month radiographic PFS rate of 67% and median rPFS of 9.1 months.
• The FDA granted Celcuity's request to submit the gedatolisib New Drug Application (NDA) via the Real-Time Oncology Review (RTOR) program, with the first pre-submission made in September 2025 and final submission expected in Q4 2025.

Sentiment

Score: 8

Explanation: The strong positive clinical trial results for gedatolisib in a significant indication, coupled with substantial capital raises that significantly improve the company's liquidity position, outweigh the increased operating losses typical for a clinical-stage biotech. The FDA's RTOR designation further enhances the positive outlook for regulatory approval. While losses are increasing, they are expected as the company advances its pipeline towards commercialization.

Positives

• Gedatolisib triplet and doublet regimens demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) in the PIK3CA wild-type (WT) cohort of the Phase 3 VIKTORIA-1 clinical trial.
• The gedatolisib triplet achieved a 7.3-month incremental improvement in median PFS (9.3 months vs 2.0 months for fulvestrant) and a 76% reduction in risk of disease progression or death (HR 0.24).
• The gedatolisib doublet achieved a 5.4-month incremental improvement in median PFS (7.4 months vs 2.0 months for fulvestrant) and a 67% reduction in risk of disease progression or death (HR 0.33).
• Gedatolisib is the first inhibitor targeting the PAM pathway to demonstrate positive Phase 3 results in patients with HR+/HER2-/PIK3CA WT advanced breast cancer whose disease progressed on or after treatment with a CDK4/6 inhibitor.
• The median duration of response (DOR) for the gedatolisib triplet was 17.5 months and for the doublet was 12.0 months, which are the highest reported for an endocrine therapy-based regimen in 2L HR+/HER2advanced breast cancer.
• The gedatolisib regimens were generally well tolerated in the VIKTORIA-1 trial, with mostly low-grade treatment-related adverse events (TRAEs) and low discontinuation rates (2.3% for triplet, 3.1% for doublet).
• The company successfully raised approximately $91.6 million in net proceeds from an Equity Offering and $194.9 million in net proceeds from a Convertible Notes Offering in July 2025, significantly enhancing liquidity.
• An additional $30.0 million Term D Loan was disbursed in September 2025, providing approximately $27.8 million in net proceeds.
• The FDA granted the request for gedatolisib NDA submission via the Real-Time Oncology Review (RTOR) program, indicating potential for an expedited review process.
• The Phase 1b/2 CELC-G-201 trial for mCRPC showed promising preliminary 6-month radiographic PFS rates (67% overall, 74% for 120mg dose) with a generally well-tolerated safety profile and no dose-limiting toxicities.
• The company believes its current capital resources, combined with available borrowings, will fund operations through 2027.

Negatives

• Net loss significantly increased by 47% to $43.8 million for the three months ended September 30, 2025, and by 68% to $126.1 million for the nine months ended September 30, 2025.
• Research and development expenses increased by 27% and 52% for the three and nine months, respectively, reflecting higher costs associated with ongoing clinical trials and commercialization efforts.
• General and administrative expenses saw substantial increases of 221% and 156% for the three and nine months, respectively, primarily due to increased employee and consulting expenses, including non-cash stock-based compensation.
• The company has not generated any revenue to date and has incurred cumulative losses and negative cash flows from operations since its inception.
• Interest expense increased by 37% to $4.6 million for the three months and 57% to $11.0 million for the nine months ended September 30, 2025, due to new debt issuances.
• Interest income decreased by 9% for the nine months ended September 30, 2025, primarily due to lower market interest rates, partially offset by a higher invested cash balance.
• The accumulated deficit grew to approximately $397.9 million as of September 30, 2025.

Risks

• Changes to U.S. or international trade policies, including tariffs, quotas, and other restrictions, could increase costs for equipment or materials, adversely affecting business, results of operations, and financial condition.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses, leadership changes, regulatory reform, government shutdowns) could hinder the ability to obtain guidance and timely approval of product candidates.
• The company's substantial indebtedness ($331.3 million aggregate principal amount as of September 30, 2025) could limit cash flow, increase vulnerability to adverse economic conditions, and impair the ability to satisfy debt obligations.
• Inability to generate sufficient funds or maintain adequate cash reserves to pay amounts due under indebtedness, including repurchasing convertible notes upon a fundamental change or paying principal at maturity.
• Financial and other restrictive covenants in loan agreements could limit the company's ability to operate its business, raise capital, or make payments under other indebtedness.
• Provisions in the Indenture for the convertible notes could delay or prevent an otherwise beneficial takeover of the company by increasing acquisition costs or discouraging third parties.

Future Outlook

The company expects research and development and general and administrative expenses to increase as it continues to develop gedatolisib, conduct ongoing Phase 3 clinical trials (VIKTORIA-1 and VIKTORIA-2), the Phase 1b/2 CELC-G-201 trial, and pursue other business development activities. Sales and marketing expenses are also anticipated to rise in preparation for the potential commercial launch of gedatolisib. The company expects to complete its final NDA submission to the FDA in the fourth quarter of 2025. Topline data for the PIK3CA MT cohort of the VIKTORIA-1 trial is expected in late Q1 2026 or Q2 2026. Management believes current cash, cash equivalents, short-term investments, and available borrowings will provide sufficient capital to fund operations through 2027, but acknowledges that additional capital may be sought to finance future expenditures and growth opportunities.

Management Comments

• "We believe gedatolisibs unique mechanism of action, differentiated chemical structure, favorable pharmacokinetic properties, and intravenous route of administration offer distinct advantages over currently approved and investigational therapies that target PI3K, AKT, or mTORC1 alone or together."
• "The gedatolisib regimens represent a new potential standard of care for patients with HR+/HER2-, PIK3CA WT advanced breast cancer whose disease progressed on or after treatment with a CDK4/6 inhibitor."
• "We plan to continue to increase our research and development expenses for the foreseeable future as we seek to continue to develop gedatolisib, including conducting the VIKTORIA-1 Phase 3 clinical trial, the CELC-G-201 Phase 1b/2 clinical trial and the VIKTORIA-2 Phase 3 clinical trial."
• "We anticipate that our general and administrative expenses will continue to increase in future periods, reflecting both increased costs in connection with the potential future commercialization of gedatolisib, an expanding infrastructure, and increased professional fees associated with public company regulatory developments and requirements, and other compliance matters."
• "Based on our current business plan, we believe that our current cash, cash equivalents and short-term investments, together with available borrowings under the A&R Loan Agreement, will provide sufficient cash to finance our operations through 2027."

Industry Context

Celcuity operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically targeting solid tumors with its lead candidate, gedatolisib, a pan-PI3K/AKT/mTOR inhibitor. The positive Phase 3 results for gedatolisib in HR+/HER2advanced breast cancer, particularly in PIK3CA WT patients who progressed on CDK4/6 inhibitors, represent a significant breakthrough. This positions gedatolisib as a potential new standard of care in a challenging patient population, differentiating it from existing therapies that often face limitations due to isoform-specific inhibition or challenging toxicity profiles. The FDA's RTOR designation further highlights the potential for gedatolisib to address an unmet medical need. The company's expansion into mCRPC and endometrial cancer trials demonstrates a broader strategic approach to leverage gedatolisib's mechanism of action across multiple indications, aligning with industry trends of maximizing therapeutic asset value.

Comparison to Industry Standards

• The hazard ratios for the gedatolisib triplet (HR 0.24) and doublet (HR 0.33) in the VIKTORIA-1 PIK3CA WT cohort are more favorable than any previously reported Phase 3 trial for patients with HR+/HER2advanced breast cancer.
• The 7.3-month incremental improvement in median PFS for the gedatolisib triplet and 5.4-month improvement for the doublet over fulvestrant are higher than any reported by any Phase 3 trial for patients with HR+/HER2advanced breast cancer receiving at least their second line of therapy.
• Gedatolisib is the first inhibitor targeting the PAM pathway to demonstrate positive Phase 3 results in patients with HR+/HER2-/PIK3CA WT advanced breast cancer whose disease progressed on or after treatment with a CDK4/6 inhibitor, a significant unmet need.
• The median DOR and incremental ORR improvement relative to control for the gedatolisib triplet and doublet are the highest reported for an endocrine therapy-based regimen in 2L HR+/HER2advanced breast cancer.
• In the B2151009 Phase 1b trial, gedatolisib combined with palbociclib and endocrine therapy achieved an ORR of 85% in treatment-naive patients (Arm A), comparing favorably to the PALOMA-2 study (ORR=55%) for palbociclib plus letrozole.
• For patients who received prior hormonal therapy alone or with a CDK 4/6 inhibitor (Arms B, C, D) in the B2151009 trial, ORR ranged from 36% to 77%, exceeding the PALOMA-3 study (ORR=25%) for palbociclib plus fulvestrant.
• Gedatolisib demonstrated a more favorable toxicity profile compared to other oral PI3K inhibitors; in its Phase 1b trial, only 7% of patients experienced Grade 3 or 4 hyperglycemia, significantly lower than the 39% reported for the FDA-approved oral p110-specific inhibitor PIQRAY in its pivotal trial. Discontinuation due to TRAEs was less than 9% for gedatolisib, compared to 26% for alpelisib (PIQRAY).

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that could reasonably be expected to have a material adverse effect on the business, financial condition, and results of operations.

Related Party Transactions

• Brightstone Venture Capital Fund, LP, where Director David Dalvey is a General Partner, adopted and subsequently terminated 10b5-1 plans for the sale of Celcuity Inc. common stock. A new plan was adopted on August 19, 2025, for the sale of up to 125,000 shares from November 18, 2025, through November 18, 2026.

Stakeholder Impact

• **Shareholders**: Potential for significant value creation due to highly positive Phase 3 clinical trial results for gedatolisib and progress towards NDA submission. However, recent equity and convertible debt offerings, along with ongoing stock-based compensation, will result in dilution. Increased net losses will continue to impact accumulated deficit.
• **Employees**: Increased stock-based compensation and expanding infrastructure suggest continued investment in personnel, potentially boosting morale and retention. Commercial headcount additions indicate future job growth related to gedatolisib launch.
• **Customers (Future Patients)**: Gedatolisib's strong efficacy and manageable safety profile in advanced breast cancer (PIK3CA WT) offers a new, potentially superior treatment option for patients whose disease has progressed on prior therapies. Promising early data in mCRPC also suggests future benefits for prostate cancer patients.
• **Creditors**: The company has significantly increased its debt burden with the convertible notes and additional term loans. While liquidity is strong, the ability to service this debt and meet conversion/repurchase obligations depends on future commercial success and continued access to capital.
• **Suppliers/Partners**: Ongoing clinical trials and commercialization preparations will likely lead to increased engagement and payments to contract research organizations, contract manufacturing organizations, and other third-party service providers.

Next Steps

• Complete final New Drug Application (NDA) submission to the FDA in the fourth quarter of 2025 for gedatolisib.
• Continue enrollment for the Phase 3 VIKTORIA-2 clinical trial for first-line HR+/HER2advanced breast cancer.
• Continue the Phase 1b/2 CELC-G-201 clinical trial for metastatic castration resistant prostate cancer, including further dose exploration to determine the Recommended Phase 2 Dose (RP2D).
• Enroll an additional 12 participants in the Phase 2 portion of the CELC-G-201 study at the determined RP2D.
• Present additional results from cohort 1 of the VIKTORIA-1 Phase 3 clinical trial at a medical conference later this year.
• Anticipate topline data for the PIK3CA mutant-type (MT) cohort of the VIKTORIA-1 Phase 3 trial in late Q1 2026 or Q2 2026.
• Potentially draw on the increased Term E Loan ($100.0 million) upon FDA approval of gedatolisib in second-line wild-type advanced breast cancer patients post CDK4/6 inhibitor therapy.
• Potentially draw on the new Term F Loans (up to three $40.0 million tranches) upon achievement of certain trailing three months product revenue thresholds.
• Potentially draw on the new Term G Loan ($150.0 million) at the lenders' sole discretion upon company request.
• Continue to increase research and development expenses to advance gedatolisib and other pipeline candidates.
• Increase sales and marketing expenses in anticipation of gedatolisib's potential commercial launch.

Key Dates

Recommendation

The filing presents compelling evidence for a 'strong buy' recommendation, particularly for investors with a higher risk tolerance in the biotechnology sector. The Phase 3 VIKTORIA-1 trial results for gedatolisib in HR+/HER2advanced breast cancer (PIK3CA WT cohort) are exceptionally positive, demonstrating statistically significant and clinically meaningful improvements in PFS that surpass historical benchmarks. The hazard ratios and incremental PFS benefits are highly favorable, positioning gedatolisib as a potential new standard of care. The FDA's Real-Time Oncology Review (RTOR) designation and anticipated NDA submission in Q4 2025 suggest an expedited path to market. Furthermore, the company has substantially strengthened its financial position with over $286 million in net proceeds from recent equity and convertible debt offerings, providing a cash runway through 2027. While the company continues to incur significant losses, this is typical for a clinical-stage biotech advancing a promising pipeline. The strong clinical data, regulatory progress, and robust liquidity significantly de-risk the investment, offering substantial upside potential upon approval and commercialization.

Keywords

Gedatolisib, Breast Cancer, PI3K/AKT/mTOR Inhibitor, Phase 3 Clinical Trial, VIKTORIA-1, HR+/HER2-, PIK3CA WT, Metastatic Castration Resistant Prostate Cancer, mCRPC, CELC-G-201, FDA RTOR, NDA Submission, Biotechnology, Oncology, Clinical Stage, Convertible Notes, Equity Offering, Debt Financing